B8.7 antigen expression on B-CLL cells and its relationship to the LMW-BCGF responsiveness.
In this work, we studied the expression of B8.7 antigen on B lymphocytes from patients suffering from B type chronic lymphocytic leukemia (B-CLL) as well as on non Hodgkin lymphoma cells (NHL). B8.7 is an activation marker, which has been reported to be associated with the capacity of activated B cells to respond to LMW-BCGF. B lymphocytes of 11 out of 22 patients tested were B8.7 positive. With the exception of one case, LMW-BCGF is able to induce DNA synthesis by these cells in the absence of costimulation by anti-mu antibodies (anti-mu Ab). The LMW-BCGF dependent proliferation of these malignant cells is inhibited by the anti-B8.7 monoclonal antibody (anti-B8.7 MoAb), in the same line as that of normal B cells. These results obtained with monoclonal B cells confirm that the B8.7 molecule is involved in the signalling pathway of the LMW-BCGF.
Karray
S
S
Unité INSERM U 131, Clamart, France.
Leprince
C
C
Merle-Beral
H
H
Debre
P
P
Richard
Y
Y
Galanaud
P
P
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology; D008875:Middle Aged; D008970:Molecular Weight
D000911:Antibodies, Monoclonal; D000944:Antigens, Differentiation, B-Lymphocyte; C059492:B8.7 antigen, human; D014408:Biomarkers, Tumor; D007376:Interleukin-2; D015847:Interleukin-4